The estimated Net Worth of Alicia Grande is at least $8.32 Milion dollars as of 27 December 2023. Ms Grande owns over 8,666 units of Catalyst Pharmaceuticals Inc stock worth over $1,152,480 and over the last 17 years she sold CPRX stock worth over $6,606,292. In addition, she makes $558,275 as Chief Accounting Officer, VP oraz Treasurer & CFO at Catalyst Pharmaceuticals Inc.
Ms has made over 23 trades of the Catalyst Pharmaceuticals Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently she exercised 8,666 units of CPRX stock worth $168,640 on 27 December 2023.
The largest trade she's ever made was exercising 200,000 units of Catalyst Pharmaceuticals Inc stock on 6 November 2017 worth over $94,000. On average, Ms trades about 34,808 units every 131 days since 2007. As of 27 December 2023 she still owns at least 59,223 units of Catalyst Pharmaceuticals Inc stock.
You can see the complete history of Ms Grande stock trades at the bottom of the page.
Alicia Grande is the Chief Accounting Officer, VP, Treasurer & CFO at Catalyst Pharmaceuticals Inc.
As the Chief Accounting Officer, VP oraz Treasurer & CFO of Catalyst Pharmaceuticals Inc, the total compensation of Ms Grande at Catalyst Pharmaceuticals Inc is $558,275. There are 6 executives at Catalyst Pharmaceuticals Inc getting paid more, with Patrick McEnany having the highest compensation of $3,371,560.
Ms Grande is 50, she's been the Chief Accounting Officer, VP oraz Treasurer & CFO of Catalyst Pharmaceuticals Inc since . There are 13 older and 2 younger executives at Catalyst Pharmaceuticals Inc. The oldest executive at Catalyst Pharmaceuticals Inc is Charles O'Keeffe, 80, who is the Lead Independent Director.
Alicia's mailing address filed with the SEC is 355 ALHAMBRA CIRCLE, SUITE 801, , CORAL GABLES, FL, 33134.
Over the last 18 years, insiders at Catalyst Pharmaceuticals Inc have traded over $35,595,986 worth of Catalyst Pharmaceuticals Inc stock and bought 7,401,098 units worth $7,307,159 . The most active insiders traders include Pharmaceutical Inc Biomarin, Patrick J Mcenany oraz Steve Miller. On average, Catalyst Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $1,097,019. The most recent stock trade was executed by David S Tierney on 21 August 2024, trading 15,000 units of CPRX stock currently worth $60,150.
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
Catalyst Pharmaceuticals Inc executives and other stock owners filed with the SEC include: